SAKK 16/18: Immune-modulatory radiotherapy to enhance the effects of neoadjuvant PD-L1 blockade after neoadjuvant chemotherapy in patients with resectable stage III (N2) non-small cell lung cancer (NSCLC)-A multicenter phase II trial.

被引：0
|
作者：
Mauti, Laetitia A.
Finazzi, Tobias
Holer, Lisa
Bettini, Adrienne
Konig, David
Fruh, Martin
Haefliger, Simon
Addeo, Alfredo
Mark, Michael Thomas
Buess, Martin
Froesch, Patrizia
Janthur, Wolf Dieter
Waibel, Christine
Ackermann, Christoph J.
Dorn, Patrick
Scheibe, Bernhard
Pless, Miklos
Guckenberger, Matthias
Prince, Spasenija Savic
Rothschild, Sacha
机构：
[1] Kantonsspital Winterthur, Dept Oncol, Winterthur, Switzerland
[2] Univ Basel Hosp, Clin Radiotherapy & Radiat Oncol, Basel, Switzerland
[3] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[4] HFR Hop Fribourgeois, Dept Oncol, Fribourg, Switzerland
[5] Univ Basel Hosp, Dept Med Oncol, Basel, Switzerland
[6] Univ Basel Hosp, Ctr Comprehens Canc, Basel, Switzerland
[7] Kantonsspital St Gallen, Dept Oncol Hematol, St Gallen, Switzerland
[8] Univ Bern, Inselspital, Bern Univ Hosp, Dept Med Oncol, Bern, Switzerland
[9] Univ Hosp HUG, Dept Oncol, Geneva, Switzerland
[10] Kantonsspital Graubuenden, Div Oncol Hematol, Chur, Switzerland
[11] St Claraspital Basel, Dept Oncol, Basel, Switzerland
[12] Oncol Inst Southern Switzerland, Bellinzona, Switzerland
[13] Kantonsspital Aarau, Dept Oncol Hematol, Aarau, Switzerland
[14] Kantonsspital Baden, Dept Oncol Hematol, Baden, Switzerland
[15] Spital Thun, Dept Oncol, Thun, Switzerland
[16] Univ Bern, Bern Univ Hosp, Inselspital, Dept Thorac Surg, Bern, Switzerland
[17] Univ Zurich Hosp, Dept Radiat Oncol, Zurich, Switzerland
[18] Univ Hosp Basel, Inst Med Genet & Pathol, Pathol, Basel, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8547
引用
收藏
页数：1
相关论文
共 50 条
  • [11] SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients with Stage IIIA(N2) NSCLC - A Multicenter Single-Arm Phase II Trial
    Rothschild, S.
    Zippelius, A.
    Savic, S.
    Gonzalez, M.
    Weder, W.
    Xyrafas, A.
    Rusterholz, C.
    Pless, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S1025 - S1025
  • [12] Phase II trial of gemcitabine and cisplatin (GC) as neoadjuvant chemotherapy in unresectable stage III non-small cell lung cancer (NSCLC).
    Crino, L
    Mazzoni, F
    Maestri, A
    Calandri, C
    Selvaggi, G
    Scagliotti, GV
    De Marinis, F
    Gregorc, V
    Darwish, S
    Tonato, M
    ANNALS OF ONCOLOGY, 2000, 11 : 108 - 108
  • [13] Phase 2 trial of neoadjuvant toripalimab with chemotherapy for resectable stage III non-small-cell lung cancer
    Zhao, Ze-Rui
    Yang, Chao-Pin
    Chen, Si
    Yu, Hui
    Lin, Yong-Bin
    Lin, Yao-Bin
    Qi, Han
    Jin, Jie-Tian
    Lian, Shan-Shan
    Wang, Yi-Zhi
    You, Jin-Qi
    Zhai, Wen-Yu
    Long, Hao
    ONCOIMMUNOLOGY, 2021, 10 (01):
  • [14] Adjuvant Radiation Therapy in Clinical Stage III (N2) Non-Small Cell Lung Cancer after Neoadjuvant Chemotherapy
    Komiya, T.
    Takamori, S.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E8 - E8
  • [15] Neoadjuvant combined treatment for stage III non-small cell lung cancer (NSCLC): Results of a prospective phase II trial
    Thomas, M
    Rube, C
    Semik, M
    Klinke, F
    VonEiff, M
    VandeLoo, J
    2ND INTERNATIONAL CONGRESS ON LUNG CANCER, 1996, : 431 - 433
  • [16] Association of tumour mutational burden (TMB) with outcomes in stage IIIA(N2) non-small cell lung cancer (NSCLC) patients treated with neoadjuvant chemotherapy and durvalumab: prospective analysis of the multicenter single-arm phase II trial SAKK16/14
    Alborelli, I
    Jermann, P. M.
    Leonards, K.
    Manzo, M.
    Keller, E.
    Zippelius, A.
    Eboulet, E., I
    Betticher, D.
    Frueh, M.
    Britschgi, C.
    Peters, S.
    Mark, M.
    Ochsenbein, A. F.
    Janthur, W. -D
    Waibel, C.
    Mach, N.
    Froesch, P.
    Pless, M.
    Prince, Savic S.
    Rothschild, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 174 - 175
  • [17] AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).
    Ross, Helen J.
    Kozono, David E.
    Urbanic, James John
    Williams, Terence Marques
    DuFrane, Carter
    Bara, Ilze
    Schulze, Katja
    Brockman, Jane Michelle
    Wang, Xiaofei F.
    Gao, Junheng
    Vokes, Everett E.
    Stinchcombe, Tom
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [18] Phase II study of neoadjuvant chemotherapy with paclitaxel and cisplatin in Stage IIIA N2 non-small cell lung cancer.
    Choi, IS
    Oh, DY
    Kim, DW
    Kim, YT
    Kim, TY
    Yoo, CK
    Kim, YW
    Heo, DS
    Bang, YJ
    Kim, NK
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 692S - 692S
  • [19] The combination of gemcitabine and cisplatin as neoadjuvant chemotherapy for early stage non-small cell lung carcinoma (NSCLC): An interim analysis of a phase II trial.
    Aydiner, A
    Kiyik, M
    Cikrikcioglu, S
    Kosar, F
    Gurses, A
    Turna, A
    Yazar, A
    Dilege, S
    Goksel, T
    Cakan, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 695S - 695S
  • [20] Effects of Neoadjuvant Therapy on Programmed Cell Death Ligand 1 (PD-L1) Expression and Immune Microenviroment in Non-Small Cell Lung Cancer (NSCLC)
    Tomaszewski, Kristen
    Huynh, Tiffany
    Kem, Marina
    Mino-Kenudson, Mari
    MODERN PATHOLOGY, 2018, 31 : 753 - 754
12345